TSPO ligand residence time influences human glioblastoma multiforme cell death/life balance

Apoptosis

Volumn 20, Issue 3, 2015, Pages 383-398

  Costa, Barbara ^a   Da Pozzo, Eleonora ^a   Giacomelli, Chiara ^a   Taliani, Sabrina ^a   Bendinelli, Sara ^a   Barresi, Elisabetta ^a   Da Settimo, Federico ^a   Martini, Claudia ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Apoptosis; Irreversible TSPO ligand; Mitochondrial membrane permeability transition (MPT) pore; Residence time; Translocator protein (18 kDa); U87MG cells

Indexed keywords

APOPTOSIS INDUCING FACTOR; DIGITONIN; IRDE MPIGA; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MITOCHONDRIAL PROTEIN; MITOCHONDRIAL TRANSLOCATOR PROTEIN; PHOSPHATIDYLSERINE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; ANTINEOPLASTIC AGENT; ANXIOLYTIC AGENT; INDOLE DERIVATIVE; LIGAND; N,N-DI-N-BUTYL-5-CHLORO-2-(4-CHLOROPHENYL)INDOL-3-YLGLYOXYLAMIDE; PROTEIN BINDING; THIOCYANIC ACID DERIVATIVE; TSPO PROTEIN, HUMAN;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CELL DEATH; CELL SURVIVAL; CELL SUSPENSION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG MECHANISM; DRUG PROTEIN BINDING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BINDING SITE; CELL CYCLE; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; GENE EXPRESSION; GENETICS; GLIA; KINETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTI-ANXIETY AGENTS; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; CLINICAL TRIALS AS TOPIC; GABA ANTAGONISTS; GENE EXPRESSION; HUMANS; INDOLES; KINETICS; LIGANDS; MEMBRANE POTENTIAL, MITOCHONDRIAL; NEUROGLIA; PROTEIN BINDING; RECEPTORS, GABA; THIOCYANATES;

EID: 84925538183     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-014-1063-3     Document Type: Article

References (82)

1. Batarseh A, Papadopoulos V (2010) Regulation of translocator protein 18 kDa (TSPO) expression in health and diseases states. Mol Cell Endocrinol 327:1-12
2. Costa B, Da Pozzo E, Martini C (2012) Translocator protein as a promising target for novel anxiolytics. Curr Top Med Chem 12:270-285
3. Taliani S, Da Settimo F, Da Pozzo E, Chelli B, Martini C (2009) Translocator protein ligands as promising therapeutic tools for anxiety disorders. Curr Med Chem 16:3359-3380
4. Barron AM, Garcia-Segura LM, Caruso D et al (2013) Ligand for translocator protein reverses pathology in a mouse model of Alzheimer's disease. J Neurosci 33:8891-8897
5. Daugherty DJ, Selvaraj V, Chechneva OV, Liu XB, Pleasure DE, Deng W (2013) A TSPO ligand is protective in a mouse model of multiple sclerosis. EMBO Mol Med 5:891-903
6. Papadopoulos V, Lecanu L (2009) Translocator protein (18 kDa) TSPO: an emerging therapeutic target in neurotrauma. Exp Neurol 219:53-57
7. Girard C, Liu S, Adams D et al (2012) Axonal regeneration and neuroinflammation: roles for the translocator protein 18 kDa. Neuroendocrinol 24:71-81
8. Rupprecht R, Papadopoulos V, Rammes G et al (2010) Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov 9:971-988
9. Qi X, Xu J, Wang F, Xiao J (2012) Translocator protein (18 kDa): a promising therapeutic target and diagnostic tool for cardiovascular diseases. Oxid Med Cell Longev 2012:162934
10. Caballero B, Veenman L, Gavish M (2013) Role of mitochondrial translocator protein (18 kDa) on mitochondrial-related cell death processes. Recent Pat Endocr Metab Immune Drug Discov 7:86-101
11. Ikezaki K, Black KL (1990) Stimulation of cell growth and DNA synthesis by peripheral benzodiazepine. Cancer Lett 49:115-120
12. Hardwick M, Fertikh D, Culty M, Li H, Vidic B, Papadopoulos V (1999) Peripheral-type benzodiazepine receptor in human breast cancer: correlation of breast cancer cell aggressive phenotype with PBR expression, nuclear localization, and PBR-mediated cell proliferation and nuclear transport of cholesterol. Cancer Res 59:831-842
13. Akech J, Sinha Roy S, Das SK (2005) Modulation of cholinephosphotransferase activity in breast cancer cell lines by Ro5-4864, a peripheral benzodiazepine receptor agonist. Biochem Biophys Res Commun 333:35-41
14. Bono F, Lamarche I, Prabonnaud V, Le Fur G, Herbert JM (1999) Peripheral benzodiazepine receptor agonists exhibit potent antiapoptotic activities. Biochem Biophys Res Commun 265:457-461
15. Strohmeier R, Roller M, Sänger N, Knecht R, Kuhl H (2002) Modulation of tamoxifen-induced apoptosis by peripheral benzodiazepine receptor ligands in breast cancer cells. Biochem Pharmacol 64:99-107
16. Leducq N, Bono F, Sulpice T et al (2003) Role of peripheral benzodiazepine receptors in mitochondrial, cellular, and cardiac damage induced by oxidative stress and ischemia-reperfusion. J Pharmacol Exp Ther 306:828-837
17. Okaro AC, Fennell DA, Corbo M, Davidson BR, Cotter FE (2002) PK11195, a mitochondrial benzodiazepine receptor antagonist, reduces apoptosis threshold in Bcl-XL and Mcl-1 expressing human cholangiocarcinoma cells. Gut 51:556-561
18. Decaudin D, Castedo M, Nemati F et al (2002) Peripheral benzodiazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo. Cancer Res 62:1388-1393
19. Xia W, Spector S, Hardy L et al (2000) Tumor selective G2/M cell cycle arrest and apoptosis of epithelial and hematological malignancies by BBL22, a benzazepine. PNAS 97:7494-7499
20. Maaser K, Höpfner M, Jansen A et al (2001) Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. Br J Cancer 85:1771-1780
21. Sutter AP, Maaser K, Höpfner M et al (2002) Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human esophageal cancer cells. Int J Cancer 102:318-327
22. Sutter AP, Maaser K, Barthel B, Scherübl H (2003) Ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in oesophageal cancer cells: involvement of the p38MAPK signalling pathway. Br J Cancer 89:564-572
23. Walter RB, Raden BW, Cronk MR, Bernstein ID, Appelbaum FR, Banker DE (2004) The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. Blood 103:4276-4284
24. Chelli B, Lena A, Vanacore R et al (2004) Peripheral benzodiazepine receptor ligands: mitochondrial transmembrane potential depolarization and apoptosis induction in rat C6 glioma cells. Biochem Pharmacol 68:125-134
25. Chelli B, Rossi L, Da Pozzo E et al (2005) PIGA (N,N-Di-n-butyl-5-chloro-2-(4-chlorophenyl)indol-3-ylglyoxylamide), a new mitochondrial benzodiazepine-receptor ligand, induces apoptosis in C6 glioma cells. ChemBioChem 6:1082-1088
26. Park SY, Cho N, Chang I et al (2005) Effect of PK11195, a peripheral benzodiazepine receptor agonist, on insulinoma cell death and insulin secretion. Apoptosis 10:537-544
27. Jordà EG, Jiménez A, Verdaguer E et al (2005) Evidence in favour of a role for peripheral-type benzodiazepine receptor ligands in amplification of neuronal apoptosis. Apoptosis 10:91-104
28. Shoukrun R, Veenman L, Shandalov Y et al (2008) The 18-kDa translocator protein, formerly known as the peripheral-type benzodiazepine receptor, confers proapoptotic and antineoplastic effects in a human colorectal cancer cell line. Pharmacogenet Genomics 18:977-988
29. Banker DE, Cooper JJ, Fennell DA, Willman CL, Appelbaum FR, Cotter FE (2002) PK11195, a peripheral benzodiazepine receptor ligand, chemosensitizes acute myeloid leukemia cells to relevant therapeutic agents by more than one mechanism. Leuk Res 26:91-106
30. Hirsch T, Decaudin D, Susin SA et al (1998) PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotection. Exp Cell Res 241:426-434
31. Oudard S, Carpentier A, Banu E et al (2003) Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J Neurooncol 63:81-86
32. Zisterer DM, Hance N, Campiani G, Garofalo A, Nacci V, Williams DC (1998) Antiproliferative action of pyrrolobenzoxazepine derivatives in cultured cells: absence of correlation with binding to the peripheral-type benzodiazepine binding site. Biochem Pharmacol 55:397-403
33. Gorman AM, O'Beirne GB, Regan CM, Williams DC (1989) Antiproliferative action of benzodiazepines in cultured brain cells is not mediated through the peripheral-type benzodiazepine acceptor. J Neurochem 53:849-855
34. Alexander BE, Roller E, Klotz U (1992) Characterization of peripheral-type benzodiazepine binding sites on human lymphocytes and lymphoma cell lines and their role in cell growth. Biochem Pharmacol 44:269-274
35. Hans G, Wislet-Gendebien S, Lallemend F et al (2005) Peripheral benzodiazepine receptor (PBR) ligand cytotoxicity unrelated to PBR expression. Biochem Pharmacol 69:819-830
36. Scarf AM, Auman KM, Kassiou M (2012) Is there any correlation between binding and functional effects at the translocator protein (TSPO) (18 kDa)? Curr Mol Med 12:387-397
37. Tummino PJ, Copeland RA (2008) Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry 47:5481-5492
38. Guo D, Hillger JM, IJzerman AP, Heitman LH (2014) Drug-target residence time: a case for G protein-coupled receptors. Med Res Rev 34:856-892
39. Taliani S, Da Pozzo E, Bellandi M et al (2010) Novel irreversible fluorescent probes targeting the 18 kDa translocator protein: synthesis and biological characterization. J Med Chem 53:4085-4093
40. Primofiore G, Da Settimo F, Taliani S et al (2004) N, N-dialkyl-2-phenylindol-3-ylglyoxylamides. A new class of potent and selective ligands at the peripheral benzodiazepine receptor. J Med Chem 47:1852-1855
41. Chang-Liu CM, Woloschok GE (1997) Effect of passage number on cellular response to DNA-damaging agents: cell survival and gene expression. Cancer Lett 26:77-86
42. Wenger SL, Senft JR, Sargent LM, Bamezai R, Bairwa N, Grant SG (2004) Comparison of established cell lines at different passages by karyotype and comparative genomic hybridization. Biosci Rep 24:631-639
43. Chelli B, Salvetti A, Da Pozzo E et al (2008) PK 11195 differentially affects cell survival in human wild-type and 18 kDa Translocator protein-silenced ADF astrocytoma cells. J Cell Biochem 105:712-723
44. Vandesompele J, De Paepe A, Speleman F (2002) Elimination of primer-dimer artifacts and genomic coamplification using a two-step SYBR green I real-time RT-PCR. Anal Biochem 303:95-98
45. Costa B, Salvetti A, Rossi L et al (2006) Peripheral benzodiazepine receptor: characterization in human T-lymphoma Jurkat cells. Mol Pharmacol 69:37-44
46. Costa B, Bendinelli S, Gabelloni P et al (2013) Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor. PLoS One 8:e72281
47. Keats E, Khan ZA (2012) Unique responses of stem cell-derived vascular endothelial and mesenchymal cells to high levels of glucose. PLoS One 7:e38752
48. Smiley ST, Reers M, Mottola-Hartshorn C et al (1991) Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci USA 88:3671-3675
49. Di Lisa F, Blank PS, Colonna R et al (1995) Mitochondrial membrane potential in single living adult rat cardiac myocytes exposed to anoxia or metabolic inhibition. J Physiol 486:1-13
50. Perry SW, Norman JP, Barbieri J, Brown EB, Gelbard HA (2011) Mitochondrial membrane potential probes and the proton gradient: a practical usage guide. Biotechniques 50:98-115
51. Stolarczyk M, Naruszewicz M, Kiss AK (2013) Extracts from Epilobium sp. herbs induce apoptosis in human hormone-dependent prostate cancer cells by activating the mitochondrial pathway. J Pharm Pharmacol 65:1044-1054
52. Agarwal C, Singh RP, Agarwal R (2002) Grape seed extract induces apoptotic death of human prostate carcinoma DU145 cells via caspases activation accompanied by dissipation of mitochondrial membrane potential and cytochrome c release. Carcinogenesis 23:1869-1876
53. Cossarizza A, Baccarani-Contri M, Kalashnikova G, Franceschi C (1993) A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochem Biophys Res Commun 197:40-45
54. Fadok VA, Voelker DR, Campbell PA et al (1992) Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 148:2207-2216
55. Li B, Chauvin C, De Paulis D et al (2012) Inhibition of complex I regulates the mitochondrial permeability transition through a phosphate-sensitive inhibitory site masked by cyclophilin D1. Biochim Biophys Acta 1817:1628-1634
56. Veenman L, Levin E, Weisinger G et al (2004) Peripheral-type benzodiazepine receptor density and in vitro tumorigenicity of glioma cell lines. Biochem Pharmacol 68:689-698
57. Giusti L, Costa B, Viacava P et al (2004) Peripheral type benzodiazepine receptor in human parathyroid glands: up-regulation in adenoma. J Endocrinol Invest 27:826-831
58. Boujrad N, Vidic B, Papadopoulos V (1996) Acute action of choriogonadotropin on Leydig tumor cells: changes in the topography of the mitochondrial peripheral-type benzodiazepine receptor. Endocrinology 137:5727-5730
59. Delavoie F, Li H, Hardwick M et al (2003) In vivo and in vitro peripheral-type benzodiazepine receptor polymerization: functional significance in drug ligand and cholesterol binding. Biochemistry 42:4506-4519
60. Cleary J, Johnson KM, Opipari AW Jr, Glick GD (2007) Inhibition of the mitochondrial F1F0-ATPase by ligands of the peripheral benzodiazepine receptor. Bioorg Med Chem Lett 17:1667-1670
61. Bernardi P (1999) Mitochondrial transport of cations: channels, exchangers, and permeability transition. Physiol Rev 79:1127-1155
62. Broaddus WC, Bennett JP Jr (1990) Peripheral-type benzodiazepine receptors in human glioblastomas: pharmacologic characterization and photoaffinity labeling of ligand recognition site. Brain Res 518:199-208
63. Lueddens HW, Newman AH, Rice KC, Skolnick P (1986) AHN 086: an irreversible ligand of "peripheral" benzodiazepine receptors. Mol Pharmacol 29:540-545
64. Newman AH, Lueddens HW, Skolnick P, Rice KC (1987) Novel irreversible ligands specific for "peripheral" type benzodiazepine receptors: (±)-, (+)-, and (-)-1-(2-chlorophenyl)-N-(1-methylpropyl)-N-(2-isothiocyanatoethyl)-3-isoquinolinecarboxamide and 1-(2-isothiocyanatoethyl)-7-chloro-1,3-dihydro-5-(4-chlorophenyl)-2H-1,4-benzodiazepin-2-one. J Med Chem 30:1901-1905
65. McCabe RT, Schoenheimer JA, Skolnick P, Newman AH, Rice KC, Reig JA, Klein DC (1989) [3H]AHN 086 acylates peripheral benzodiazepine receptors in the rat pineal gland. FEBS Lett 244:263-267
66. Alenfall J, Batra S (1996) Photoaffinity labeling of peripheral benzodiazepine receptors in R-3327 Dunning prostatic tumors. Biochem Pharmacol 51:1009-1013
67. van Engeland M, Nieland LJ, Ramaekers FC et al (1998) Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 31:1-9
68. Galluzzi L, Zamzami N, de La Motte Rouge T, Lemaire C, Brenner C, Kroemer G (2007) Methods for the assessment of mitochondrial membrane permeabilization in apoptosis. Apoptosis 12:803-813
69. Copeland RA, Pompliano DL, Meek TD (2006) Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5:730-739
70. Guo D, Hillger JM, IJzerman AP, Heitman LH (2014) Drug-target residence time: a case for G protein-coupled receptors. Med Res Rev 34:856-892
71. Sutter AP, Maaser K, Gerst B, Krahn A, Zeitz M, Scherübl H (2004) Enhancement of peripheral benzodiazepine receptor ligand-induced apoptosis and cell cycle arrest of esophageal cancer cells by simultaneous inhibition of MAPK/ERK kinase. Biochem Pharmacol 67:1701-1710
72. Sileikyte J, Blachly-Dyson E, Sewell R et al (2014) Regulation of the mitochondrial permeability transition pore by the outer membrane does not involve the peripheral benzodiazepine receptor (TSPO). J Biol Chem 289:13769-13781
73. Azarashvili T, Baburina Y, Grachev D et al (2014) Carbenoxolone induces permeability transition pore opening in rat mitochondria via the translocator protein TSPO and connexin43. Arch Biochem Biophys 558:87-94
74. Azarashvili T, Grachev D, Krestinina O et al (2007) The peripheral-type benzodiazepine receptor is involved in control of Ca2+-induced permeability transition pore opening in rat brain mitochondria. Cell Calcium 42:27-39
75. Li J, Wang J, Zeng Y (2007) Peripheral benzodiazepine receptor ligand, PK11195 induces mitochondria cytochrome c release and dissipation of mitochondria potential via induction of mitochondria permeability transition. Eur J Pharmacol 560:117-122
76. Pastorino JG, Simbula G, Gilfor E, Hoek JB, Farber JL (1994) Protoporphyrin IX, an endogenous ligand of the peripheral benzodiazepine receptor, potentiates induction of the mitochondrial permeability transition and the killing of cultured hepatocytes by rotenone. J Biol Chem 269:31041-31046
77. Chelli B, Falleni A, Salvetti F, Gremigni V, Lucacchini A, Martini C (2001) Peripheral-type benzodiazepine receptor ligands: mitochondrial permeability transition induction in rat cardiac tissue. Biochem Pharmacol 61:695-705
78. Kinnally KW, Zorov DB, Antonenko YN, Snyder SH, McEnery MW, Tedeschi H (1993) Mitochondrial benzodiazepine receptor linked to inner membrane ion channels by nanomolar actions of ligands. Proc Natl Acad Sci USA 90:1374-1378
79. Berson A, Descatoire V, Sutton A et al (2001) Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation. J Pharmacol Exp Ther 299:793-800
80. Obame FN, Zini R, Souktani R, Berdeaux A, Morin D (2007) Peripheral benzodiazepine receptor-induced myocardial protection is mediated by inhibition of mitochondrial membrane permeabilization. Pharmacol Exp Ther 323:336-345
81. Giorgio V, von Stockum S, Antoniel M et al (2013) Dimers of mitochondrial ATP synthase form the permeability transition pore. Proc Natl Acad Sci USA 110:5887-5892
82. Seneviratne MS, Faccenda D, De Biase V, Campanella M (2012) PK11195 inhibits mitophagy targeting the F1Fo-ATPsynthase in Bcl-2 knock-down cells. Curr Mol Med 12:476-482